Tonix presented preclinical data on gastric cancer models at AACR

Tonix Pharmaceuticals (TNXP) presented data in a poster presentation at the American Association for Cancer Research, AACR, 2025 Annual Meeting, held April 25-30, 2025, in Chicago, IL. The presentation titled, “TFF2-mediated CXCR4 partial agonism outperforms CXCR4 antagonism in reducing murine gastric cancer by suppressing PMN-MDSC generation,” demonstrated positive data in gastric cancer animal models. In the AACR presentation, a fusion protein of murine trefoil factor family member 2- murine serum albumin was studied. Tonix is developing human TFF2-human serum albumin as TNX-1700. “The combination therapy of mTFF2-MSA with anti-PD1 treatment shows promise in reducing immunosuppression in the tumor microenvironment in animal models,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “We are excited to develop TNX-1700 as the lead program in our immuno-oncology pipeline, by testing potential dosing strategies, and establishing potential clinical biomarkers through preclinical models.”